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A B S T R A C T
Neurodegenerative disease are frequently characterized by microglia activation and/or leukocyte infiltration in
the parenchyma of the central nervous system and at the molecular level by increased oxidative modifications of
proteins, lipids and nucleic acids. NADPH oxidases (NOX) emerged as a novel promising class of pharmacolo-
gical targets for the treatment of neurodegeneration due to their role in oxidant generation and presumably in
regulating microglia activation. The unique function of NOX is the generation of superoxide anion (O2•–) and
hydrogen peroxide (H2O2). However in the context of neuroinflammation, they present paradoxical features
since O2•–/H2O2 generated by NOX and/or secondary reactive oxygen species (ROS) derived from O2•–/H2O2 can
either lead to neuronal oxidative damage or resolution of inflammation. The role of NOX enzymes has been
investigated in many models of neurodegenerative diseases by using either genetic or pharmacological ap-
proaches. In the present review we provide a critical assessment of recent findings related to the role of NOX in
the CNS as well as how the field has advanced over the last 5 years. In particular, we focus on the data derived
from the work of a consortium (Neurinox) funded by the European Commission's Programme 7 (FP7). We discuss
the evidence gathered from animal models and human samples linking NOX expression/activity with neuroin-
flammation in neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and Creutzfeldt–Jakob
disease as well as autoimmune demyelinating diseases like multiple sclerosis (MS) and chronic inflammatory
demyelinating polyneuropathy (CIDP). We address the possibility to use measurement of the activity of the
NOX2 isoform in blood samples as biomarker of disease severity and treatment efficacy in neurodegenerative
disease. Finally we clarify key controversial aspects in the field of NOX, such as NOX cellular expression in the
brain, measurement of NOX activity, impact of genetic deletion of NOX in animal models of neurodegeneration
and specificity of NOX inhibitors.
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1. Introduction
1.1. The family of NADPH oxidases
The family of NADPH oxidases (NOX) contains seven members
NOX1, NOX2, NOX3, NOX4, NOX5, DUOX1 and DUOX2 (for review,
see [1]). They are membrane proteins comprising 6 transmembrane
domains (7 for DUOX1 and 2), which have as sole known function to
catalyze the formation of superoxide anion (O2•–) and hydrogen per-
oxide (H2O2). In terms of mechanism, all NOX isoforms function as
electron transporters. Electrons from cytoplasmic NADPH are trans-
ferred across membranes by the NOX protein complex, via intermediate
flavin adenine dinucleotide and heme prosthetic groups, to reduce
molecular oxygen in the extracellular space or in the lumen of in-
tracellular organelles. During this reaction, oxygen and NADPH are
consumed while NADP+, intracellular H+ and extra-cytosolic O2•– are
produced. O2•– is rapidly dismutated into H2O2 either spontaneously or
upon catalysis by superoxide dismutases (SOD). While O2•– is the pri-
mary product of the reaction catalyzed by NOX, the kinetics of con-
version to H2O2 appears to vary among NOX isoforms. For example,
only minute amounts of O2•– and high amounts of H2O2 are detected as
a result of NOX4 activity and only H2O2 is detected from DUOX1 and
DUOX2 activities. Each NOX isoform is characterized by specific tissue
distribution and mechanism of activation [1].
Because of its high expression and activity in phagocytes, the NOX2
isoform was originally named gp91phox (phox: phagocyte oxidase).
NOX2 (encoded by the CYBB gene) was formally identified in 1976 [2]
and its biochemistry has been extensively studied. At resting state,
NOX2 forms a stable but inactive complex with the transmembrane
protein, p22phox (CYBA). Activation requires protein kinase C-depen-
dent phosphorylation, leading to the translocation of cytosolic subunits
p47phox (NCF1), p67phox (NCF2) and p40phox (NCF4) to the cell mem-
brane, where they physically interact with the p22phox-NOX2 complex
and one of the small Rho GTP-binding proteins, Rac1 or 2 (Fig. 1). Si-
milarly to NOX2, NOX1 and NOX3 require the interaction with p22phox
and specific cytosolic components (NOXO1 (NOX organizer type 1),
NOXA1 (NOX activator type 1)) for activity. NOX4 also requires
p22phox, but is constitutively active. DUOX1 and 2 require the ma-
turation factors DUOXA1 and 2. NOX5 and DUOXes are activated by
direct phosphorylation and/or increase of intracellular Ca2+. Under
physiological conditions, NOX are essential mediators of different
processes, and mutations and polymorphisms of NOX genes can have
notable effects [3]. Different mutations affecting NOX2 holoenzyme
cause increased susceptibility to infections by certain pathogens due to
deficient neutrophil oxidative burst and impaired bacterial killing in
humans and mice, a disease known as chronic granulomatous disease
[4]. In addition, a deficiency in functional NOX2 complex has been
associated with the development of various autoimmune chronic in-
flammatory conditions [5]. Mutations in one of the component of the
DUOX2 complex lead to congenital hypothyroidism while mutations
affecting the NOX3 complex lead to balance impairment in rodents.
Mutations in NOX1 predispose patients to inflammatory bowel disease
[6]. In contrast, loss of function mutations in NOX4, NOX5 or DUOX1
genes have not been reported, and the NOX4 and DUOX1 knockout
mice do not display an obvious spontaneous phenotype. While the ab-
sence of at least certain NOX-derived oxidants have pathological con-
sequences, excessive oxidant production by NOX enzymes can con-
tribute to oxidative tissue damage in a wide range of diseases, such as
cardiovascular diseases [7], pancreatitis [8], and several diabetic
complications [9]. Importantly numerous studies have identified the
involvement of NOX in various CNS disorders [10].
1.2. Neuroinflammation and neurodegenerative diseases
The most frequent neurodegenerative diseases (ND) are Alzheimer's
disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis
(ALS), Huntington's disease (HD) and multiple sclerosis (MS).
Symptomatic treatments exist for some ND like PD and potent im-
munomodulatory drugs show efficacy in MS. However no disease
modifying therapies are yet available for ND. The symptoms of ND are
largely due to the progressive impairment of neuronal function and
vary depending on the type of neuronal cells and brain regions affected
(e.g., cortex, hippocampus, substantia nigra, spinal cord, striatum or
peripheral nerves) [11–13]. ND can be triggered by cell death, protein
aggregation or molecules released by injured neurons. The initiating
factors leading to neurodegeneration can vary greatly, but several
features are shared in most ND: abnormal aggregation of specific pro-
teins, spatio-temporal spreading of aggregated proteins in the CNS
parenchyma, a sustained inflammatory response, and oxidation of li-
pids, proteins and nucleic acids [14,15]. MS differs from other ND, as it
is an autoimmune disease leading to the destruction of the myelin
sheath and neuronal loss is secondary to the myelin loss [13]. MS
presents typical features of inflammation as it is characterized by in-
filtration of leukocytes in the brain and spinal cord. In other ND like
AD, PD and ALS, the cell types governing neuroinflammation are mostly
astrocytes and microglia [14]. Early neuroinflammatory features are
mostly inconspicuous, as the classical signs of inflammation (calor,
dolor, rubor, and tumor) are not observed. Moreover, typical anti-in-
flammatory drugs, such as non-steroidal anti-inflammatory drugs (most
of which inhibit the activity of cyclooxygenase-1 and/or−2) have been
unsuccessful in treating ND, or have even been harmful [16]. Similar to
peripheral inflammation, neuroinflammation is most likely a primary
response of the host aimed at protecting neurons by removing harmful
stimuli and initiating healing processes, However, when neuroin-
flammation is sustained/prolonged, it may become detrimental to
neuronal cells and contributes to the progression of ND (for review, see
[14]. Thus, identifying novel drug targets that control neuroin-
flammation represents an important therapeutic approach for ND, al-
though this approach has so far been relatively unexplored [14,17].
1.3. NOX as potential regulators of neuroinflammation
Among the potential regulators of neuroinflammation, NOX re-
present a novel promising class of targets for the treatment of ND. As
indicated, oxidative modifications to proteins, lipids and DNA are al-
most always observed in ND, but the source of oxidants remains elusive.
Increased oxidative stress resulting from increased oxidant formation
has been known for many years to be a central feature in ND [18]. It
was once thought that oxidants were directly involved in neuronal
death due to their toxic properties, but evidence points towards subtler
regulatory roles of at least some oxidants [19,20]. Indeed, increased
oxidant generation in specific cellular and subcellular compartments
leads to oxidative modifications of macromolecules, which modulate
Fig. 1. Schematic structure of the phagocyte NADPH oxidase NOX2. The catalytic com-
plex is formed by the membrane association of NOX2 and p22phox. Upon activation a
cytosolic complex is formed and translocates to the membrane in order to form an active
O2•–-generating enzymatic system.
S. Sorce et al. Free Radical Biology and Medicine 112 (2017) 387–396
388
the transcription and other signaling pathways controlling neuroin-
flammation. Oxidants are key components of the neuroinflammatory
response, but therapeutic approaches targeting reactive oxygen species
have so far been unsuccessful [18]. In particular, the absence of benefit
of antioxidant strategies may be due to the fact that the molecules used
lacked in vivo efficacy or that the overall effect of antioxidants is
complicated by a concomitant attenuation of regulatory role of oxi-
dants. A novel approach consists of targeting a primary source of O2•–/
H2O2 (e.g., NOX) rather than ‘scavenging’ oxidants after they have been
formed and/or undergone metabolism.
There are several potential sources of cellular oxidants, as O2•–/
H2O2 are the byproducts of the activity of mitochondria, peroxisomes
and xanthine oxidase among others. Compared with these sources,
however, NOX are different in the sense that their sole function is the
generation of O2•–/H2O2. A role of excessive NOX-formed O2•–/H2O2
and secondary oxidants derived from them in CNS pathology is known
since the first report that NOX2 gene knockout mice are partially pro-
tected from brain ischemia [21]. Similar to neuroinflammation, which
can be protective or deleterious when over-activated, NOX present
paradoxical features: NOX-derived O2•–/H2O2 can lead to oxidative
damage and pathology, or be beneficial by regulating key physiological
functions, including the resolution of inflammation in autoimmune
diseases, including MS. Thus, depending on the pathology, the ther-
apeutic approach should either enhance or mitigate NOX activity (see
graphical abstract). We have previously thoroughly reviewed the lit-
erature concerning the expression of NOX isoforms in the CNS as well as
their presumed contributions to CNS disorders in models of AD, PD, ALS
and MS [10,22,23]. With the present review we would like to provide
an update on the role of NOX in the CNS as well as how the field has
advanced over the last 5 years. In particular, we focus on key findings
obtained by the Neurinox consortium (www.neurinox.eu) which had
the goal to study some of the most controversial aspects of NOX biology
in the CNS.
2. Advances and findings on NOX in the CNS and ND
2.1. NOX expression and localization
The cellular localization of NOX enzymes is still a matter of debate.
The scientific literature reports the expression of several NOX isoforms
in virtually every cell type of the CNS [23]. However, many studies
were performed by using non-validated commercial antibodies without
appropriate controls. Validated isoform-specific NOX antibodies are
scarce because the lipophilic structure of these proteins makes the
generation of specific antibodies difficult. Recent available data how-
ever have allowed to deduce the precise cellular localization of NOX
isoforms in the CNS by using a combination of qPCR experiments [24],
RNAseq analyses of isolated cell types from mouse and human brain
[25], and immunohistological signals using the few available specific
NOX antibodies, which have been validated using NOX gene knockout
mice [24,26].
2.1.1. NOX2 and NOX4 are the main NOX isoforms expressed in the CNS
Remarkably, NOX expression data indicate that under physiological
conditions most NOX isoforms are expressed only to a negligible extent
in the CNS. Specifically, qPCR shows that NOX1, NOX3, NOX5, DUOX1
and DUOX2 are undetectable or at the limit of detection in the human
brain as well as in the mouse spinal cord and cerebral cortex [24,25].
NOX4 is detected in CNS tissue , and RNAseq data indicate that it is
expressed mostly in the mouse endothelium, while very low amounts
are also present in fetal astrocytes and oligodendrocytes. Similarly,
NOX1 and NOX5 are expressed in the vasculature [27], but no clear
evidence indicates that they are present in CNS parenchyma. Interest-
ingly, DUOXA1 was detected at high levels in the CNS by qPCR and
RNAseq, most likely in microglia, however only in the mouse brain
[24,25]. DUOXA1 is known to play a role as maturation factor of
DUOX1, but since DUOX1 is absent in microglia, it may have a pre-
sently unknown role in mouse microglia. Nonetheless, the most re-
levant NOX isoform in the CNS in terms of expression is NOX2. More-
over, NOX2 expression is strikingly enhanced in the CNS of patients and
mouse models of ND [24,26].
2.1.2. NOX2 and its subunits are enriched in microglia
Several lines of evidence indicate that, in the CNS, NOX2 is ex-
pressed mostly in microglia. First of all, NOX2 and subunits are key
markers of phagocytes and are under the control of the transcriptional
factor PU.1, the main transcriptional regulator of phagocytes [28]. In
humans, the MoAb 48 monoclonal NOX2 antibody [29] shows distinct
cellular co-localization of NOX2 with the microglial marker Iba-1, but
not with markers for astrocytes (GFAP) or neurons (MAP2 or NF) [26].
Although no suitable antibody is available for NOX2 im-
munohistochemistry in mice, the following indirect evidence indicate
microglial expression of NOX2: (i) concomitant increase of NOX2 ex-
pression and its subunits p47phox, p67phox, p40phox, rac1 and p22phox
with the microglial markers CD68, Iba-1 and CD11b in a mouse model
of ALS [24]; (ii) absence of NOX2 detection in organotypic cerebellar
slices where microglia was specifically ablated by ganciclovir in tga20/
TK mice [22]; (iii) enrichment of NOX2 in microglial populations as
confirmed by transcriptional profiling of isolated brain cells [25].
2.1.3. NOX2 is present in neural adult stem cells
In addition to microglia, NOX2 is also expressed in small popula-
tions of neural stem cells of the dentate gyrus and subventricular zone
of the adult brain, where NOX2 plays a role in the proliferation and
multipotency of mouse neural stem cells [30,31,98].
Fig. 2 summarizes NOX expression in the cells of the CNS. Our
analysis cannot exclude the possibility that, in specific circumstances
(e.g., during neuronal development) or in particular subpopulations of
cells or brain areas, the expression of NOX isoforms can be elicited, e.g.,
NOX1 in substantia nigra [32] or NOX4 in pericytes [33]. Nevertheless,
in ND, the expression of NOX2 increases greatly, largely due to mi-
croglia activation or CNS invasion by peripheral myeloid cells. The
latter cannot easily be distinguished from resident microglia, especially
in pathological situations associated with blood-brain-barrier damage.
In any case, it is unlikely that NOX2 is a key source of oxidants in
mature neurons. Instead, alternative sources of neuronal oxidants might
Fig. 2. Cellular localization of NOX2 in the CNS. NOX2 is expressed by microglia and
invading monocytes/macrophages as well as adult neural stem cells. All other NOX iso-
forms are present in brain vascular cells.
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derive from mitochondria [34], MICAL proteins [35], monoamine
oxidase [36] and cytochrome P450 [37] among others.
Having clarified that NOX2 expression is closely related to microglia
activity offers the possibility to better understand and interpret the
impact of NOX2 genetic or pharmacological targeting. In light of the
multifaceted and often discordant consequences of microglia con-
tribution in ND, it could then be reasoned that NOX2-derived oxidants
in these cells can similarly exert beneficial and detrimental effects,
depending on the particular context.
3. Small molecules targeting NOX enzymes
3.1. NOX inhibitors
Most information on the role of NOX in the CNS derives from studies
using the natural product apocynin. Numerous published studies report
a striking beneficial effect of apocynin on ND in animal models, via
decreasing microglia activation and improving symptoms and survival
(reviewed in [22,38]). However, there are some notable exception to
such an apparent beneficial effect, including an ALS mouse model
where apocynin is inactive [39] and the Tg19959 mice model of AD,
where apocynin is deleterious [40]. Importantly, we [41] and others
[42] have shown that apocynin is not a NOX inhibitor in the sense that
it does not show affinity for the NOX enzyme. Apocynin may appear as
a NOX inhibitor at high concentrations because either it interferes with
peroxidase-dependent assays for oxidants [43] or may inhibit the
translocation of p47phox in neutrophils, thereby indirectly inhibiting
NOX2 activation [44]. A recent study using a mitochondria-targeted
apocynin argues for mitochondrial oxidant scavenging as the basis for
its anti-inflammatory and neuroprotective effects in a mouse model of
PD [45]. Thus, studies documenting a therapeutic effect of apocynin in
models of neurodegenerative diseases do not necessarily imply a role of
NOX.
The case of apocynin highlights the challenges faced when
searching for NOX inhibitors. This is the reason why we [41,46,47] and
others [48] have developed a strict flowchart for identification and
characterization of NOX inhibitory molecules [49]. This approach is
designed to exclude false positives including those resulting from cell
toxicity and interference with oxidant-measuring systems (Fig. 3). This
flowchart emphasizes the requisite of (i) using NOX cell free assays for
screening small molecules and determines the mode of action of iden-
tified inhibitors, (ii) use several detection systems to measure the ac-
tivity of NADPH oxidases, ideally by separately measuring O2•– and
H2O2, (iii) use of methods allowing measuring NOX-dependent sub-
strate consumption (i.e. O2 and NADPH) to exclude molecules inter-
fering with ROS detection systems and (iv) importantly for the devel-
opment of NOX based drugs, clear documentation of in vivo
pharmacokinetics and pharmacodynamics parameters. Bona fide NOX
inhibitors should have the two following characteristics: i) they should
inhibit NOX-derived oxidants in both cellular and NOX purified mem-
branes and ii) they should block oxygen consumption in cells and/or
NADPH consumption in NOX purified membranes. Below is an ex-
haustive list of small molecules NOX inhibitors which have passed this
flowchart.
(i) Diphenyleneiodonium (DPI) potently inhibits all NOX isoforms
with high affinity [46], most likely by irreversible binding to the
cytosolic FAD domain of NOX [50]. However DPI lacks drug-like
properties due to mitochondria toxicity and low solubility. DPI is
not specific for NOX as it inhibits other electron transport chains,
including NO synthase, xanthine oxidase among others. None-
theless DPI is a useful pharmacological tool in vitro and should be
systematically used as a reference NOX inhibitor. As a rule of
thumb, a signal not inhibited by DPI is most likely not due to NOX
[49]. However caution is still warranted in interpretation since a
lucigenin bioluminescent signal inhibited by DPI was recently
shown to be due to cytochrome P450 [51].
(ii) GSK2795039, a novel drug-like small molecule, is the first identi-
fied NOX inhibitor to show isoform-specificity. Its mode of action
is through competition for the NADPH binding site of NOX2.
GSK2795039 is orally available, non-toxic, CNS-permeable and
inhibits NOX2 activity in vivo [41]. GSK2795039 has not yet been
tested in an animal model of ND.
(iii) A subset of N-substituted phenothiazines - but not non-substituted
phenothiazines - inhibits NOX activity [47]. N-substituted phe-
nothiazines have been used for decades as anti-psychotic agents,
and upon administration can give rise to micromolar concentra-
tions in the CNS. It remains unclear how N-substituted phe-
nothiazines inhibit NOX, although they do not show isoform spe-
cificity. N-substituted phenothiazines, including thioridazine and
perphenazine, are known to be promiscuous molecules with nu-
merous potential modes of action in the CNS. However, since they
are already used as human therapeutics, they offer an attractive
perspective for potential repurposing in ND (see below for their use
in a mouse model of ALS).
(iv) Ebselen and ebselen-sulfur analogues (e.g. thr101) were identified
as inhibitors of the interaction between p22phox and p47phox in a
high throughput screening [52]. These molecules inhibit NOX2 in
a membrane assay and in whole cells expressing NOX1, NOX4 and
NOX5. Although low concentration of ebselen is toxic to cells, it
was confirmed as bona fide inhibitor of NOX2 in precedent [53]
and subsequent [48] studies. Ebselen is known for a long time for
its neuroprotective properties, in particular against stroke [54].
Unfortunately ebselen has multiple potential pharmacological
targets with a strong redox component [55] and is thus not very
useful to demonstrate a NOX-dependent activity.
Fig. 3. Flow-chart for identification of bona fide NOX inhibitory drugs.
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(v) Celastrol is a natural extract derived from Tripterygium wilfordii, a
plant used in traditional Chinese medicine. Celastrol inhibits
NOX2–derived ROS and substrate consumption in NOX2 mem-
brane assays and cells expressing NOX1, NOX2, NOX4 and NOX5,
including NOX2-dependent oxygen consumption in neutrophils
and NADPH in NOX2 membrane assay [41,46]. However, its
practicality as a NOX inhibitor is limited due to cell toxicity, the
fact that it is colored (orange) and thus interferes with several
assays. Similarly to ebselen, it is a promiscuous molecule with
multiple described mode of action and is therefore not very useful
to demonstrate a NOX-dependent activity.
Recently, the team of Zielonka and Kalyanaraman have developed
their own flow-chart to identify NOX2 inhibitors using HL60 cells, a
human neutrophil-like cell with high levels of NOX2 expression and
activity [48,56]. They use several distinct read-outs for O2•– and H2O2
in high throughput format and confirm the hits by measuring toxicity
and NOX2-dependent oxygen consumption by HL60 cells. This ap-
proach confirmed the activity of DPI as well as ebselen and analogues
but infirmed the NOX inhibitory of apocynin. It also allowed the
identification of several novel small molecules, including a novel small
molecule of great interest Thioxo-dihydroquinazolin-one (aka com-
pound 43) [48]. Identified molecules now awaits confirmation and
potential mode of action in NOX2 semi-recombinant assays.
The favorable impact of antioxidants and anti-inflammatory mole-
cules like apocynin adds further evidence that targeting neuroin-
flammation and oxidative stress may be beneficial in ND. The potential
therapeutic values of apocynin and other reported non-validated NOX
inhibitors is not questioned, but their efficacy in a model of ND is not
sufficient evidence of a role of NOX and should be interpreted with
caution. Only the use of CNS-permeable and fully validated NOX in-
hibitors, such as GSK2795039 will provide valid information on the role
of NOX2 in ND.
3.2. NOX activators
Only few attempts have so far been made to identify substances
inducing NOX2 activity for treating inflammatory disease although
small molecules that activate ROS production have previously been
identified [57–61]. Quinolinone derivatives are a new class of mole-
cules that enhance NOX2 function has been recently developed aiming
for treatment of CNS autoimmune diseases [62,99]. Identified NOX
agonists are currently in a phase of optimization for bioavailability and
pharmacokinetics. They have anti-inflammatory properties and are able
to decrease the pro-inflammatory role of TNF-α in the low nanomolar
range. Future studies will show whether they are suitable for clinical
use as first in class NOX2 activators for treatment of autoimmune dis-
eases.
3.3. Mechanisms regulated by NOX2 in peripheral circulating cells and
autoimmune disease
In reference to the scheme in the graphical abstract, a large part of
Neurinox effort was dedicated to the study of the oxidants generated by
NOX enzymes in the context of autoimmune diseases, including MS,
and other peripheral autoimmune demyelinating diseases such as
chronic inflammatory demyelinating polyneuropathy (CIDP) and
Guillain-Barré syndrome (GBS). More specifically, NOX2 activity in
macrophages and other antigen presenting cells has an anti-in-
flammatory effect and regulate activation of autoreactive T cells [63].
This unexpected fact was originally discovered in a genetic study per-
formed to identify the most important polymorphic loci controlling
autoimmune chronic inflammatory diseases, using models for rheu-
matoid arthritis and multiple sclerosis [64]. This led to the identifica-
tion of a polymorphism in the coding sequence of Ncf1 (neutrophil
cytosolic factor 1), the gene coding for p47phox, a subunit essential to
control NOX2-dependent formation of O2•– [64,65]. It has been esti-
mated that approximately half of inbred rat strains and half of the wild
rat population carries an allele in Ncf1 that leads to a significantly
lower NOX2-mediated oxidative burst [66]. The regulatory role of
oxidants is likely to be conserved between species. Consistent with this
notion, there is also an extensive polymorphism in the human Ncf1
region which is associated with autoimmune diseases [67]. Im-
portantly, this allele confers strong protection against autoimmune
diseases. This finding opened the provocative possibility that NOX
agonists could serve as therapeutics in autoimmune disorders [68].
Since then, a protective role of NOX2-derived oxidants has been re-
produced in several different models of autoimmune disorders, in-
cluding models for MS and Guillain Barré [69–71]. The NOX2-depen-
dent anti-inflammatory effect is mediated by several different
pathways: (i) downregulation of autoreactive T cells during antigen
presentation [63]; (ii) autocrine downregulation of inflammatory
macrophages [5,72]; (iii) downregulation of STAT1 mediated activa-
tion of the interferon pathway [73,74]; and (iv) promotion of a pro-
tective effect by neutrophil extracellular traps (NETS) formed by neu-
trophils [75]. Further studies aimed to identify both the chemical
nature of the oxidants involved and the respective roles played by these
potentially protective pathways in MS and peripheral neuropathies are
needed. Indeed, it is still unclear at present if excess oxidants in the CNS
are counteracting the protective effect of the peripheral inflammatory
attack, thereby promoting neurodegeneration [76].
3.4. Genetic and pharmacological inhibition of NOX in models of ND
The contribution of NOX-derived oxidants to the development of ND
was studied in detail in two models of ND known for their intense
neuroinflammatory reaction: ALS and Creutzfeldt–Jakob disease (CJD).
ALS is a severe ND affecting motoneurons and leading to complete
paralysis and death. ALS is a typical neuroinflammatory disease char-
acterized by an increase in pro-inflammatory markers, microgliosis and
astrocytosis. In most cases, the underlying causes of ALS are unknown.
However, the identification of novel ALS-causing mutations indicates
that mechanisms leading to the aggregation of specific proteins and
RNA pathology (e.g., TDP-43, SOD1, FUS and c9orf72) are a key pa-
thological event in ALS. There are no treatments for ALS, and Riluzole,
a small molecule known to decrease glutamate levels in the CNS, is the
only drug prescribed for ALS patients, although it has very modest ef-
ficacy. In both patients and animal models of ALS, the expression of
microglial NOX2 is strongly increased, specifically in affected regions of
the spinal cord [24]. Previous studies by the Engelhardt group have
shown that NOX1 and NOX2 deficiency confers prolonged survival of
transgenic mice expressing an ALS-causing mutation (SODG93A mice),
the most commonly used model for this disease [77]. NOX inhibitors
appeared as most promising therapeutics to slow down ALS progres-
sion. As mentioned above, thioridazine and perphenazine have NOX
inhibitory activity and as they are used in the treatment of humans,
they represent attractive drugs for rapid initiation of clinical trials in
ALS patients [47]. However, administration of thioridazine and per-
phenazine to SODG93A mice did not improve survival, although they
showed some benefits in secondary read-outs, such as motor function
for thioridazine and weigh loss for perphenazine [47]. Thioridazine
decreased O2•- levels and microglia activation markers in spinal cords of
SODG93A mice, yet crossing of SODG93A mice with NOX2 or NOX1 gene
knockout mice did not affect disease onset and progression, nor mi-
crogliosis, astrogliosis or motoneuron survival [24]. These results
question initial reports [77], showing a prolonged lifespan in ALS
models related to NOX2 and NOX1 deficiency.
Creutzfeldt–Jakob disease (CJD) is an incurable ND characterized at
the neuropathological level by a massive neuronal loss conferring a
spongiform aspect of the brain [78]. The causative agent of CJD is the
misfolding of prion proteins which propagates among neurons and
leads to a neuroinflammatory environment and increased microglial
S. Sorce et al. Free Radical Biology and Medicine 112 (2017) 387–396
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NOX2 expression [26]. Interestingly, NOX2 gene knockout mice in-
fected with prions did not show decreased microgliosis, but showed a
transient improvement of motor function (rotarod), decreased oxidants,
significant survival improvement and improvement of vacuoles for-
mation in the brain at terminal stage. Similarly, NOX2 greatly con-
tributes to neurotoxicity in mice treated with a neurotoxic anti-prion
antibody [79].
Together, these data show that NOX2 expression is strongly in-
creased in ND and most likely contributes to oxidant formation asso-
ciated with neurodegenerative mechanisms, although it does not seem
to limit microglia activation and microgliosis. Whereas increased NOX2
activity and oxidant generation are shared between CJD and ALS, NOX2
deletion slightly improves survival only in CJD. This suggests that the
neurotoxic cascade of CJD and ALS are different, and that targeting
NOX2-derived oxidants might be more efficient in CJD than in ALS.
Remarkably, while antioxidant-based therapies have been strikingly
unsuccessful in ALS, prion pathogenesis was shown to converge in
oxidant formation and to be efficiently mitigated both ex vivo and in
vivo by antioxidants [80]. Therefore, novel specific NOX2 inhibitors
with blood brain barrier permeability and a defined mode of action
such as GSK2795039 await further testing in prion pathogenesis and
other ND [41,81].
3.5. Measurement of NOX activity in vivo
Measuring NOX activity in tissues remains a challenge. In the lit-
erature of ND the most commonly used approach is to use a CNS tissue
homogenate to which lucigenin and NADPH are added and lucigenin-
enhanced chemiluminescence is then determined as a measure of O2•–.
However, the method of lucigenin-enhanced chemiluminescence has
well known pitfalls and limitations (see, e.g., [82]). In addition, Re-
zende et al. [51,83] recently reported that the signal measured in this
assay is due to cytochrome P450, rendering it inappropriate for de-
termination of NOX activity.
The major product of NOX is O2•–, and hydroethidine or dihy-
droethidium [84] is considered the ‘gold standard’ for O2•– determina-
tion in biological systems [85]. Importantly, previous work by Kalya-
naraman and co-workers has established that the fluorescence of
ethidium, commonly the most abundant oxidation product of hydro-
ethidine in biological systems, is not specific for O2•– [84]. Instead 2-
hydroxyethidium is the O2•– specific product. Unfortunately, ethidium
and 2-hydroxyethidine have very similar fluorescent properties, so that
fluorescence is not a specific readout for O2•– in biological systems.
Rather, a combination of chromatographic separation of ethidium and
2-hydroxyethidine coupled with fluorescent or mass spectrometry
based detection is required for the selective determination of O2•–.
Using LC-MS/MS and administering hydroethidine into the spinal cord
revealed that thioridazine decreased O2•– in the spinal cord of SOD1G93A
mice in vivo [24]. Despite this successful demonstration of a localized
decrease in O2•– in vivo, there remain a number challenges. First, such
approach cannot provide direct information on NOX activity, as the
method at best measures steady state concentration of O2•–, that is de-
termined by the rates of both formation and ‘removal’ of this reactive
species. ‘Removal’ in this context includes both dismutation of O2•– as
well as reaction of O2•– with other reactive species (e.g., nitric oxide)
giving rise to secondary oxidants. Second, the concentration of 2-hy-
droxyethidine detected following in vivo administration of hydro-
ethidine represents a snapshot only of what is likely a complex and
changing process as ND develops. Similarly, the route of administration
of hydroethidine likely affects the products detected subsequently.
Therefore, for such a probe-based approach to measure O2•–, each ex-
perimental model requires careful ‘optimization’ with regards to timing
of probe administration relative to disease process, route of probe ad-
ministration, and exposure time prior to tissue harvest and analytical
analyses of unreacted and reacted probe. Third, the biochemical ap-
proach cannot provide true information on the spatial
compartmentalization of NOX activity.
As of today, no method allowing for the live measurement of re-
active oxygen species or NOX activity in the CNS is available. Such a
probe would help understanding the respective sources of oxidants,
their dynamics, prognosis value of NOX2 activity and contribution to
ND.
3.6. NOX and oxidative biomarkers in NDs
Despite the challenges mentioned above, a large part of Neurinox
was dedicated to evaluate NOX activity and oxidized biomarkers in ND
patients. In a clinical study, NOX2 activity from peripheral neutrophils
and monocytes was directly measured in fresh whole blood of a cohort
of 83 ALS patients, and age- and gender-matched healthy controls. The
assay is based on flow cytometry and uses the cell permeable fluor-
escent dye DHR123, an unspecific probe used for diagnosis of chronic
granulomatous disease. Upon addition of a specific activator, no dif-
ference was observed between patients and healthy controls, however,
inside the ALS group, low DHR123 oxidation in leukocytes was sig-
nificantly associated with a longer survival [86]. This represents an
important finding in the field of ALS because this may be a prognosis
biomarker of the severity of ALS. More importantly, such a measure
could be implemented as surrogate biomarker to address the benefit of
a drug in clinical studies (Fig. 4A-C).
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a
neurological disorder characterized by damaged myelin sheath of the
peripheral nerves leading to progressive weakness and impaired sen-
sory function in the legs and arms. Intravenous immunoglobulin (IVIg)
therapy is used as a first-line therapy and usually provides substantial
benefit to patients. A prospective clinical study enrolled 30 CIDP pa-
tients treated with IVIg and 30 control subjects for whom NOX2 ac-
tivity/DHR123 oxidation was measured in neutrophils and monocytes
from freshly collected blood. At diagnosis NOX2 activity was sig-
nificantly increased in CIDP patients compared to controls. However,
following IVIg therapy, NOX2 activity was even more increased com-
pared to basal levels [87]. The exact cause of this observation is un-
clear, but the results are consistent with therapeutic improvement in
autoimmune demyelination being associated with enhanced NOX2.
Because of the simplicity and robustness of this assay, it could be in-
cluded systematically in clinical settings for ND. This would potentially
provide key information on inclusion criteria and the response to a
drug.
Measuring NOX2 activity in whole blood is informative of a stage of
disease. However, as previously stated, there are currently no methods/
probes available to measure O2•– or H2O2 in human CNS. For these
reasons, determining the role of NOX in human ND continues to rely on
indirect measures, such as assessment of oxidative stress. The Neurinox
consortium determined F2-isoprostanes as well as enzymatic oxidation
products of arachidonic acid (by LC-MS/MS) in cerebrospinal fluid and
plasma of patients with progressive multiple sclerosis. Compared with
controls, plasma concentrations of F2-isoprostanes and prostaglandin
F2α (PGF2α) were decreased with increasing disability score [88]. This
was in contrast to the situation in cerebrospinal fluid, where the con-
centrations of PGF2α, but not F2-isoprostanes, were significantly higher
in patients with progressive disease than controls. Cerebrospinal fluid
PGF2α was reduced with natalizumab and methylprednisolone treat-
ment, suggesting that PGF2α levels in the CSF represents reliable sur-
rogate biomarkers for evaluation of the efficacy of a drug (Fig. 4D, E).
Note that PGF2α levels remained unaffected by the use of nonsteroidal
anti-inflammatory drug in secondary progressive MS. Interestingly,
cerebrospinal fluid PGF2α did not associate with validated cere-
brospinal fluid markers of inflammation or markers of brain damage
that themselves did not associate with the disability score [88]. These
results suggest that MS progression is associated with low rather than
high systemic oxidative activity, and that this may play a role in im-
mune dysregulation with central nervous system inflammation
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accompanied by increased local cyclooxygenase-dependent lipid oxi-
dation.
4. Other redox systems in the CNS
The therapeutic approach of targeting proteins involved in redox
dysregulation in ND is not limited to NADPH oxidases and several redox
systems represent valid pharmacological targets. Dimethyl fumarate, a
small molecule activator of Nrf2, a key transcription factor of the an-
tioxidant response, has shown promising results for the treatment of
certain forms of MS [89]. Similarly, mitochondrial targeting of specific
antioxidants [90] and apocynin [91] have been reported to yield pro-
mising results in preclinical models of PD. Small molecules inhibiting
myeloperoxidase are in clinical trials for PD [92]. In the CNS, H2O2 can
be generated by the MICAL (molecule interacting with CasL) family of
enzymes, in particular by MICAL-2 which controls dendrite and synapse
formation [93]. In addition to NOX, several sources of O2•–/H2O2, in-
cluding nitric oxide synthase, monoamine oxidase, xanthine oxidase are
present in the CNS, mainly in microglia [94]. Reversible cysteine oxi-
dation by thioredoxins and peroxiredoxins are increasingly recognized
as a fine-tuning redox regulation of CNS homeostasis, similar to what is
known for phosphorylation. Fig. 5 summarizes the main localization of
several of these oxidant generators and redox regulators.
5. Concluding remarks
Our recent work has clarified NOX localization in the CNS, identi-
fied novel small molecule NOX inhibitors/activators and state-of-the-art
methods to measure O2•– in vivo, showed a strong association between
NOX2 and disease progression in ND, and indicated that NOX2 ex-
pression and activity parallels microgliosis and neuroinflammation in
ND. Importantly, however, inhibition of NOX provided at best only
limited beneficial effects in mouse models of ALS and CJD. Although
some neurodegenerative processes (e.g. following traumatic brain in-
jury) may benefit from NOX2 inhibition, it appears that this is not a
disease-modifying approach. The question as to whether Nox2-gener-
ated oxidants is beneficial, not functional or detrimental in neuro-
pathology should be addressed in priority using NOX2-deficient mice in
animal models of ND.
Despite the scientific progress, no current therapeutic is able to halt
neurodegenerative processes, in part due to difficulties in our under-
standing of the mechanisms underlying the development of ND. Indeed,
Fig. 4. Measurement of redox activity in physiological fluids of patients affected by neurodegenerative disease as predictors of disease severity and potential efficacy of a drug (surrogate
biomarkers). NOX2 activity can be measured directly in whole blood using DHR123 (A) followed by flow cytometry (B). High levels of NOX2 activity is associated with decreased survival
in ALS patients (C) [86]. Quantification of oxidation products of arachidonic acid in the cerebrospinal fluid of MS patients (D) shows that it can serve as surrogate biomarkers of the
activity of a drug treating MS (E) [88].
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the identification of potential therapeutic targets derives from neuro-
pathological observations and identification of disease-causing muta-
tions. However, the fact that a particular pathological characteristic,
such as oxidative stress, is associated with disease progression does not
mean that it is a cause of the disease (see review [19]). For example, the
presence of β-amyloid aggregates is the most clear pathological signs
related to AD, however, it is not yet clear whether therapies decreasing
β-amyloid aggregates in AD patients translate into symptomatic im-
provement and doubts arise about the validity of the original hypoth-
esis implying amyloid as major cause of the disorder [95–97]. Similarly,
the increase in number of glial cells with altered morphological status
in brain sections of different patients affected by ND has supported the
idea that this reaction contributes to disease progression. Experimental
evidence has shown that the pathogenic mechanisms are more complex.
Indeed, microglia can exert both detrimental and protective functions,
depending on the particular pathological context [14]. It appears that
similar conclusions can be taken for NOX in ND. NOX2 up-regulation is
indeed a common feature of ND and a sign of a neuroinflammatory
response, but NOX2 inhibition is not a disease-modifying treatment.
NOX2 upregulation, increased oxidant generation, microgliosis and
neuroinflammation are all associated factors of ND, but this evidence
does not necessarily mean that they are a cause, as they can be rather a
consequence of the neurodegenerative process. However, one of the key
findings of our studies shows that a correlation between NOX2 activity
and disease progression or response to treatments in patients is mea-
surable in the blood, which makes NOX2 a promising biomarker for
future evaluation of therapies for ND. Understanding the kinetics of
oxidant formation and metabolism, the relative role of various oxidant-
generating systems and their inter-dependence in the fine redox reg-
ulation will pave the way for long awaited therapeutics targeting oxi-
dative stress in CNS disorders.
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